TWI248431B - Chlorogenic acid, isochlorogenic acid composition, and pharmacology use thereof - Google Patents
Chlorogenic acid, isochlorogenic acid composition, and pharmacology use thereof Download PDFInfo
- Publication number
- TWI248431B TWI248431B TW92116577A TW92116577A TWI248431B TW I248431 B TWI248431 B TW I248431B TW 92116577 A TW92116577 A TW 92116577A TW 92116577 A TW92116577 A TW 92116577A TW I248431 B TWI248431 B TW I248431B
- Authority
- TW
- Taiwan
- Prior art keywords
- acid
- composition
- chlorogenic acid
- sars virus
- isochlorogenic
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
1248431 玖、發明說明: 【發明所屬之技術領域】 本發明涉及具有生物活性的化合物,更具體指綠原酸、異綠原酸的組合 物及其抗SARS病毒活性在製備預防和治療非典型性肺炎藥物中應用。 【先前技術】 綠原酸、異綠原酸、黃嶋物質等存在於多種植物中,例如金銀花、咖 啡、杜仲、茵陳蒿等植物中。 金,花又名雙花、銀花、忍冬花,爲忍冬科多年生纏繞性木質藤本植物 心冬的化#。我國南北各地均有分布。夏初當花蕾含t未放時採摘,暗曬或 陰乾,生用或炒用。性寒,味甘,入肺、胃、大腸經。功能:清熱解毒、疏 散風熱、凉血止病。中醫學認爲金銀花甘寒質輕,其氣清香,既能清熱解毒, 又能宣散風熱’清解之中能宣透,麟療外歧熱、溫病初期、跡廍腫之 要樂。我鼠間常以金職、生甘草適量泡茶飲用,可祕夏物暑抗溫, ’、月’、’、解渴’減取金銀彳匕、麥冬、桔梗、烏梅、甘料炮飲治療急慢性咽喉 炎。 綠原酸⑽⑽genic acid),異名:如非轉酸,是苯丙稀酿奎寧_ 類化合物巾最«的天缝物之―,主要存接—些具有清鱗毒的傳統中 ^ 士圭銀花之中’疋這些帽的功效成分之_。綠原酸的結構式如下式⑴:1248431 玖, the invention description: [Technical field of the invention] The present invention relates to a biologically active compound, more specifically to a composition of chlorogenic acid, isochlorogenic acid and its anti-SARS virus activity in the preparation of prevention and treatment of atypical Application in pneumonia drugs. [Prior Art] Chlorogenic acid, isochlorogenic acid, and xanthine substances are present in various plants, such as honeysuckle, coffee, Eucommia ulmoides, and Artemisia scoparia. Gold, flower, also known as double flower, silver flower, honeysuckle flower, is the perennial entwined woody vine of the honeysuckle family. China is distributed throughout the north and south. At the beginning of summer, when the flower buds contain t, they are picked, darkened or dried, used or fried. Sexual cold, sweet, into the lungs, stomach, large intestine. Function: clearing away heat and detoxifying, dispersing wind and heat, cooling blood and stopping disease. Chinese medicine believes that honeysuckle is sweet and cold, and its gas is fragrant. It can not only clear away heat and detoxification, but also dispel the wind and heat. It can be revealed through clearing, the heat of external treatment, the early stage of warm disease, and the swelling of the disease. fun. I often drink tea in the golden and raw licorice, but I can use the summer heat to resist the temperature, ', month', ', thirst quenching' to reduce the gold and silver carp, Ophiopogon japonicus, platycodon, ebony, and cannon. Chronic pharyngitis. Chlorogenic acid (10) (10) genic acid), synonym: if non-transacid, is a styrene-flavored quinine _ class compound towel most «the day of the seam -", mainly stored - some of the traditional scurvy Among the flowers, 'the ingredients of these caps.' The structural formula of chlorogenic acid is as follows (1):
HO COOHHO COOH
HO COOH ,異綠驗(iS〇Chl〇rogenic acid)的結構式可能如下式⑼或(ιι工)HO COOH, the structural formula of iS〇Chl〇rogenic acid may be as follows (9) or (ιι)
S=CHCOO〆 ΠS=CHCOO〆 Π
OOCCH=c (II)OOCCH=c (II)
12484311248431
可發生氣喘、纽等,但食人射則 有止血、增一血球,具有驗血凝及“時間的作用。綠原酸毒性报= 幼大鼠口服LD5()大於ig/Kg腹腔注射大於〇· 25g/Kg。 ” 义 【發明内容】 本發明的目的是提供一種綠原酸、異綠原酸的醫學新用途,特星 抗SARS病毒活性,可在製備預防、治療SARS病毒疾病的藥用中應用疋^有 本發明的另-目的是將具有抗SARS病毒活性的綠原酸或異綠魏作 主要成份組成之組合物,以製備治療或預防由^咫病毒引起疾病的藥物二 本發明的再一目的是將組合物配製成合適的劑型。 μ ° 本發明的綠原酸是從植物金銀花經水煎二次,煎液减壓濃縮至—^ 積,稀石灰乳懸濁液調PH到鹼性,離心分離,沈殿物盎2彳立旦 疋體 ,、1口里乙酉孚研勻擔 拌加入稀硫酸使pH至3,離心,上清液用2N NaOH調PH,楫、、★ 付九祝物水重么士 晶,得綠原酸純品。It can cause asthma, New Zealand, etc., but the eclipse can stop bleeding, increase blood cells, have blood test and "time effect. Chlorogenic acid toxicity = young rats oral LD5 () is greater than ig / Kg intraperitoneal injection is greater than 〇 · 25g/Kg. ” [Abstract] The object of the present invention is to provide a new medical use of chlorogenic acid and isochlorogenic acid, and the anti-SARS virus activity of the special star can be used for preparing a medicament for preventing and treating SARS virus diseases. Further application of the present invention is to provide a composition comprising chlorogenic acid or isochlorin which is active against SARS virus as a main component to prepare a medicament for treating or preventing diseases caused by prion. A further object is to formulate the composition into a suitable dosage form. μ ° The chlorogenic acid of the invention is dehydrated from the plant honeysuckle twice, and the decoction is concentrated under reduced pressure to -^, and the lime milk suspension is adjusted to pH, and the mixture is separated by centrifugation. Once the carcass, 1 mouth, 酉 酉 研 匀 匀 匀 匀 匀 匀 匀 匀 匀 匀 匀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀 稀Pure acid.
(綠原酸結構) S4. 5.2 0 1248431 綠原酸經藥理試驗證明其具有明顯的抗SARS病毒活性,活性測定採用 Vero-E6細胞作爲病毒宿主細胞(易感細胞),測樣品綠原酸對病毒感染細胞 的保護作用檢測指標爲細胞變性反應,以及感染細胞保護率。 病毒株爲BJ-01 ’師選用樣品7個稀釋度’結果證明其具有明顯的抗mrs 病毒活性。 根據綠原酸、異綠原酸具有明顯的抗SARS病毒活性,結合維生素◦的 醫學用途特點配製成新的組合物,維生素C、綠原酸或異綠原酸:維生素c 重量比爲10 : 1—1 : 10。再根據需要加入輔劑製成不同劑型的組合物。 本發明含有有效量綠原酸、異綠原酸與藥物可接受的賦形劑、載體或稀 釋劑配製成不同的藥物劑型,它可將綠原酸、異綠原酸與維生素〇與口服製 劑中的典型藥物載體和賦形劑製成口服劑,藥物載體和賦形劑包括乳糖;殿 粉及其衍生物類如玉米澱粉、羧甲基澱粉鈉等;纖維素衍生物,諸如甲基和 乙基纖維素;明膠;無機類化合物如輕質氧化鎂、滑石粉等;油,諸如植物 油、芝麻油等;包合劑如/3-環糊精;以及二元醇類如聚乙二醇。口服製劑 的可做成片劑、膠囊、乳劑、溶液等,也可應用於固體分散片、脂質體製 靶向製劑和控釋製劑等。 、 本發明含有有效量綠原酸、異綠原酸與藥物可接受的賦形載體或稀釋劑 配製成注射劑包括等滲鹽水、5%葡萄糖水溶液、注射用水、茶油、大豆油、 麻油、乙醇、甘油、丙二醇、聚乙二醇、苯甲酸苄酯;TWEEN8〇、卵填脂、 脫氧膽酸鈉、蛋黃磷脂、聚乙烯吡咯烷酮;醋酸、醋酸鈉、枸櫞酸及鈉鹽、 乳酸、酒石酸及鈉鹽、磷酸氫二鈉、磷酸二氫鈉、碳酸氫鈉和碳酸鈉;明膠、 羧甲基纖維素鈉、果膠、山梨醇溶液;肌酐、甘氨酸;亞硫酸鈉、亞硫酸氫 鈉、焦亞磷酸鈉、硫代硫酸鈉、苯曱醇、對羥基苯甲酸丁酯及乙酯酚、三氯 叔丁醇;利多卡因;腦磷脂、大豆磷脂等,注射製劑的典型形式爲粉針劑、 混懸型注射劑等。 在片劑中,可將組合物與用碳酸氫鈉與酒石酸或枸櫞酸混合組成的崩解 劑-起製成沖泡旋,當遇水時產生二氧化碳氣體使片劑迅速崩解。 1248431 —级合物也可製成氣霧劑,例如採用聚氯乙烯糊狀樹脂笨二甲酸二丁醋、 苯一甲酸二辛酯、硬脂酸鈣、硬脂酸辞等配製而成氣霧劑。 【實施方式】 取金銀花水煎2次,煎液减壓濃縮至1 : 2,加入20%石灰乳懸濁液調至 PH10左右,離心分離沈澱物,將沈澱與2倍量乙醇研勻,在攪拌下滴加5〇% 硫酉文’>谷液調至PH3,充分攪拌,離心除去固體物。濾液以2NNa〇H調至邱6, 回收乙醇,减壓烘乾,得粗提物。取粗提物溶於少量水,進行聚醯胺柱色譜 分離,以梯度乙醇-水洗脫,聚醯胺薄層檢測洗脫液,合併含有綠原酸部分, 减壓抽乾。以水進行重結晶,得綠原酸純品。 綠原酸抗SARS病毒活性結果 /則试專案:綠原酸抗SARS病毒活性的篩選(病毒-細胞標準式) 測試原理:以Vero-E6細胞作爲病毒宿主細胞(易感細胞),測試樣品 對病毒感染細胞的保護作用,檢測指標爲細胞變性反應(CPE) (Cyt〇pathic Effect)以及感染細胞保護率。 測試材料和方法:綠原酸 病毒株:BJ-01 樣品處理:樣品溶於培養液或DMS0,配成適宜的初始濃度,5倍稀釋, 各7個稀釋度。 測試方法:把Vero -E6細胞接種於96孔培養板,置37°C,5%C02培養 箱培養,分別加入SARS病毒和不同稀釋濃度的樣品,設病毒對照、細胞對 照和樣品對照。每日鏡下觀察結果,記錄CPE,幷用中性紅染色測定⑻值, 參照對照進行樣品抗SARS病毒活性作用的計算和評價。 測試結果 —濃度Ug/ml) CFE 感染細 -m - -一 — 1248431 ο 8163206 2040..1000 00.0. 457831 567332 2.2.2.2.2.1. 知顧綠似幻:「」代表細胞無病變;以加號表示細胞病變程度, <25% +,25%〜50% ++,50%〜75 +++,>75%++++。 滅雜游練#··通過比較病毒對照、細胞對照和樣品對關⑻值, 計算樣品對病毒感染細胞的保護活性,保護率W倍率,初步被認爲樣品 對病毒感染細胞具有一定的保護活性。 *揉品續麵··如果樣品的細胞毒性與細胞對照比观不做cpE 評價和保護率計算。 上述結果顯示該化合物具有的抗SARS病毒活性侧。而綠原酸的 LD5G大於lg/Kg,腹腔注射大於0 25g/Kg證明毒性較低。 實施例一 選用下列用量的藥物組合物與附加劑:(化合物··維生素=1: iw/w ) 活性化合物 400克 、 % 維生素C 經丙維生素 微粉矽膠 預膠化殿粉 硬脂酸鎂 400克 20克 60克 120克 適量 TSbo 粒 南丨樂物組合物與附加劑混合均勻,用10%預膠化殺粉聚作爲枯合 ’ w繩1L ’供乾’加人適量硬脂鴨混合,壓製成鍵劑。 實施例二 量的藥物組合物與附加劑:(化合物:維生辛= 1.9) 活性化合物 80克 f王I i.bu 10 1248431 維生素C 720克 經丙維生素 20克 微粉矽膠 48克 乙醇 適量 硬脂酸鎂 -製成 將上述藥物經合物與羥丙纖維素及微粉矽膠混合,用適量7〇%乙醇做濕 900粒 潤劑,濕法製粒,過40目篩選成顆粒,烘乾,加入硬脂酸鎂,混合,裝入 硬膠囊。 實施例三 選用下列用量的藥物組合物與附加劑:(化合物:維生素=2:1) 活性化合物 800克 維生素C 400克 蔗糖 40克 防腐劑 適量 蒸餾水 適量 ~^ 20000^1 ---- 取蒸餾水適量丄加入上述藥物組合物,邊加熱邊攪拌使溶解,過濾。另 將蔗糖和防腐劑用蒸餾水加熱溶解,在攪拌下緩緩加入上述溶液中,加蒸餾 水至全量,混合’冷藏’過漉’灌封,滅菌,得口服液。 實施例四 選用下列用量的藥物組合物與附加劑:(化合物:維生素=6:1) 活性化合物 240〇克 維生素c 4〇〇克(chlorogenic acid structure) S4. 5.2 0 1248431 Chlorogenic acid has been proved to have significant anti-SARS virus activity by pharmacological test. Vero-E6 cells are used as viral host cells (susceptible cells) for the determination of chlorogenic acid. The protective index of virus-infected cells is the cell degeneration reaction and the protection rate of infected cells. The virus strain was tested by the BJ-01 ''s sample of 7 dilutions' and proved to have significant anti-mrs virus activity. According to the chlorogenic acid and isochlorogenic acid, the anti-SARS virus activity is combined with the medical use characteristics of vitamin strontium to prepare a new composition, and the vitamin C, chlorogenic acid or isochlorogenic acid: vitamin C weight ratio is 10 : 1-1: 10. Further, adjuvants are added as needed to prepare compositions of different dosage forms. The invention comprises an effective amount of chlorogenic acid, isochlorogenic acid and a pharmaceutically acceptable excipient, carrier or diluent to prepare different pharmaceutical dosage forms, which can chlorogenic acid, isochlorogenic acid and vitamin strontium and oral administration Typical pharmaceutical carriers and excipients in the preparation are formulated as oral preparations, and pharmaceutical carriers and excipients include lactose; powders and derivatives thereof such as corn starch, sodium carboxymethyl starch, etc.; cellulose derivatives such as methyl And ethyl cellulose; gelatin; inorganic compounds such as light magnesium oxide, talc, etc.; oils such as vegetable oils, sesame oils, etc.; inclusion agents such as /3-cyclodextrin; and glycols such as polyethylene glycol. The oral preparation can be used as a tablet, a capsule, an emulsion, a solution, etc., and can also be applied to a solid dispersion tablet, a lipid system targeting preparation, and a controlled release preparation. The present invention comprises an effective amount of chlorogenic acid, isochlorogenic acid and a pharmaceutically acceptable shaped carrier or diluent formulated into an injection comprising isotonic saline, 5% dextrose in water, water for injection, tea oil, soybean oil, sesame oil, Ethanol, glycerin, propylene glycol, polyethylene glycol, benzyl benzoate; TWEEN8〇, egg fat, sodium deoxycholate, egg yolk phospholipid, polyvinylpyrrolidone; acetic acid, sodium acetate, citric acid and sodium salt, lactic acid, tartaric acid And sodium salt, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydrogencarbonate and sodium carbonate; gelatin, sodium carboxymethylcellulose, pectin, sorbitol solution; creatinine, glycine; sodium sulfite, sodium bisulfite, Jiaoya Sodium phosphate, sodium thiosulfate, benzoyl alcohol, butyl p-hydroxybenzoate and ethyl phenol, chlorobutanol; lidocaine; cephalin, soybean phospholipid, etc., the typical form of injection preparation is powder injection, mixed Suspension injections, etc. In the tablet, the composition can be made into a brewing agent with a disintegrant composed of a mixture of sodium hydrogencarbonate and tartaric acid or citric acid, and when it is in contact with water, carbon dioxide gas is generated to rapidly disintegrate the tablet. 1248431—The compound can also be made into an aerosol, for example, an aerosol formed by using a polyvinyl chloride paste resin, dibutyl phthalate, dioctyl benzoate, calcium stearate, and stearic acid. Agent. [Embodiment] Take honeysuckle water decoction 2 times, decoction concentrated to 1: 2 under reduced pressure, add 20% lime milk suspension to pH 10 or so, centrifuge to separate the precipitate, and centrifuge the precipitate with 2 times the amount of ethanol. Under stirring, 5 〇 % thiol text > gluten solution was adjusted to pH 3, stirred well, and the solid matter was removed by centrifugation. The filtrate was adjusted to Qiu 6 with 2NNa〇H, ethanol was recovered, and dried under reduced pressure to obtain a crude extract. The crude extract was dissolved in a small amount of water, separated by polyamine column chromatography, eluted with a gradient of ethanol-water, and the eluate was detected by a thin layer of polyamine. The chlorogenic acid fraction was combined and dried under reduced pressure. Recrystallization from water gives pure chlorogenic acid. Chlorogenic acid anti-SARS virus activity results / test project: screening of chlorogenic acid anti-SARS virus activity (virus-cell standard) Test principle: using Vero-E6 cells as viral host cells (susceptible cells), test sample pairs The protective effect of virus-infected cells, the detection index is the cell degeneration reaction (CPE) (Cyt〇pathic Effect) and the protection rate of infected cells. Test materials and methods: chlorogenic acid strain: BJ-01 Sample treatment: The sample is dissolved in the culture solution or DMS0, and is formulated into a suitable initial concentration, 5 times dilution, 7 dilutions each. Test method: Vero-E6 cells were seeded in a 96-well culture plate, cultured at 37 ° C in a 5% CO 2 incubator, and SARS virus and samples of different dilution concentrations were added, respectively, and virus control, cell control and sample control were set. The results of daily microscopic observations were recorded, CPE was recorded, and the value of (8) was determined by neutral red staining. The calculation and evaluation of the anti-SARS virus activity of the samples were carried out with reference to the control. Test result - concentration Ug / ml) CFE infection fine - m - - one - 1248431 ο 8163206 2040..1000 00.0. 457831 567332 2.2.2.2.2.1. Know the green like magic: "" represents the cell without lesions; Indicates the degree of cytopathic effect, <25% +, 25% to 50% ++, 50% to 75 +++, >75%++++.消杂游#·· By comparing the virus control, cell control and sample check (8) values, calculate the protective activity of the sample on virus-infected cells, the protection rate is W rate, and it is preliminarily considered that the sample has certain protective activity against virus-infected cells. . * 揉 续 · · · If the cytotoxicity of the sample and the cell control ratio do not do cpE evaluation and protection rate calculation. The above results show that the compound has an anti-SARS virus active side. The LD5G of chlorogenic acid is greater than lg/Kg, and the intraperitoneal injection is greater than 0 25g/Kg, indicating less toxicity. In the first embodiment, the following dosages of the pharmaceutical composition and the additional agent are selected: (compound··vitamin=1: iw/w) 400 g of active compound, % vitamin C, pre-gelatinized powder of magnesium stearate, 400 g of vitamin C powder 20 grams of 60 grams of 120 grams of the appropriate amount of TSbo granules Nanxun music composition and additives are evenly mixed, with 10% pre-gelatinized powdered polyglycol as a dry 'w rope 1L 'for dry' plus the right amount of hard fat duck mixed, pressed Bonding agent. Example 2 of the pharmaceutical composition and additive: (Compound: Wisconsin = 1.9) Active compound 80 g f Wang I i.bu 10 1248431 Vitamin C 720 g of vitamin C 20 g of micronized gelatin 48 g of ethanol amount of stearic acid Magnesium sulphate - prepared by mixing the above-mentioned drug mixture with hydroxypropyl cellulose and micro-powder gel, using a suitable amount of 7〇% ethanol as wet granules, wet granulation, screening through 40 mesh into granules, drying, adding hard Magnesium citrate, mixed, filled into hard capsules. The third embodiment uses the following dosages of the pharmaceutical composition and the additive: (compound: vitamin = 2:1) active compound 800 g vitamin C 400 g sucrose 40 g preservative proper amount of distilled water ~ ^ 20000 ^ 1 ---- take distilled water An appropriate amount of hydrazine is added to the above pharmaceutical composition, stirred while heating to dissolve, and filtered. Further, sucrose and a preservative are dissolved by heating in distilled water, and the mixture is slowly added to the above solution under stirring, and distilled water is added to the whole amount, mixed, refrigerated, and sterilized to obtain an oral solution. Example 4 The following dosages of pharmaceutical compositions and additives are used: (compound: vitamin = 6:1) active compound 240 g of vitamin c 4 g
Tween80 適量 11 1248431 94. δ. 2 Ο 注射用水 適量 -製成 : 45000 ml 取適量注射用水,加入上述藥物組合物,加熱,攪拌使充分溶解,加入 4%Tween80,充分攪:勻,過濾,加鹽酸調pH至6. 8,加注射用水至足量,中 空纖維超濾,精濾、,灌封,滅菌,得注射液。 【圖式簡單說明】Tween80 Appropriate amount 11 1248431 94. δ. 2 适 Injectable water amount - Made: 45000 ml Take appropriate amount of water for injection, add the above pharmaceutical composition, heat, stir to fully dissolve, add 4% Tween80, stir well: evenly, filter, add Adjust the pH of hydrochloric acid to 6.8, add water for injection to a sufficient amount, hollow fiber ultrafiltration, fine filtration, encapsulation, sterilization, and get the injection. [Simple description of the map]
1212
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW92116577A TWI248431B (en) | 2003-06-18 | 2003-06-18 | Chlorogenic acid, isochlorogenic acid composition, and pharmacology use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW92116577A TWI248431B (en) | 2003-06-18 | 2003-06-18 | Chlorogenic acid, isochlorogenic acid composition, and pharmacology use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200500336A TW200500336A (en) | 2005-01-01 |
TWI248431B true TWI248431B (en) | 2006-02-01 |
Family
ID=37429117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW92116577A TWI248431B (en) | 2003-06-18 | 2003-06-18 | Chlorogenic acid, isochlorogenic acid composition, and pharmacology use thereof |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI248431B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041703A1 (en) * | 2008-10-08 | 2010-04-15 | 株式会社 ポッカコーポレーション | Anti-sars coronavirus agent, and product containing anti-sars coronavirus agent |
-
2003
- 2003-06-18 TW TW92116577A patent/TWI248431B/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041703A1 (en) * | 2008-10-08 | 2010-04-15 | 株式会社 ポッカコーポレーション | Anti-sars coronavirus agent, and product containing anti-sars coronavirus agent |
Also Published As
Publication number | Publication date |
---|---|
TW200500336A (en) | 2005-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3991742A1 (en) | Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient | |
WO2013139111A1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
JP6656316B2 (en) | How to use cucumbers, how to use cucumbers extract and how to use drug mixtures | |
JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
WO2006063515A1 (en) | Use of radix sanguisorbae and its extract for preparing medicament to increase rbc and hemoglobin | |
WO2014010656A1 (en) | Superior blood alcohol concentration reduction accelerating agent | |
CN106176716A (en) | The new application of daphane diterpene compound pimelotide C | |
JPH0778021B2 (en) | Diarrhea virus infection inhibitor | |
CN102731597B (en) | Abelmoschus manihot extract and novel application of chemical components thereof | |
TWI248431B (en) | Chlorogenic acid, isochlorogenic acid composition, and pharmacology use thereof | |
CN101948473B (en) | New NEO-clerodane diterpenoid compound and application thereof | |
CN103417563A (en) | Application of aurantiamarin to preparation of medicine for treating acute and chronic bronchitis | |
WO2006115202A1 (en) | Composition for lessening nicotine toxicity | |
CN103933100A (en) | Preparation method of total alkaloid of Chinese mahonia stem and applications of total alkaloid of Chinese mahonia stem in preparation of drugs for preventing and treating gastric ulcer | |
JPH05170659A (en) | Composition for lowering alcohol concentration in blood | |
CN106692289B (en) | Medical application of barbat skullcap alcohol extract | |
CN100482245C (en) | Medicine composition contg. isatis root and scutellariae glucoside | |
KR101209646B1 (en) | Pharmaceutical compositions containing the extracts of Araneus ventricosus for increasing immune cell number or inhibiting metastasis of cancer or proliferation of hepatitis virus | |
KR101508561B1 (en) | Pharmaceutical composition containing extracts of mixed natural herb include avena sativa thereof for preventing and treating of Diabetic Disease | |
CN107260720A (en) | Application of the casticin in medicament for resisting ulcerative colitis is prepared | |
CN111789811B (en) | Injection solution and freeze-dried powder of honokiol for injection and preparation method thereof | |
CN111067898B (en) | Application of berberine hydrochloride in resisting carp herpesvirus II in aquaculture | |
JPH08333268A (en) | Licorice extract-formulated stable liquid | |
KR101244284B1 (en) | Lquid composition powder freezing dried male silk pupa with an increased stability | |
TW201722411A (en) | Pharmaceutical composition for treating lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |